遗传资源

一例以皮肤色素沉着为唯一临床表现的X-连锁肾上腺脑白质营养不良的诊疗和基因检测分析

展开
  • 1. 华中科技大学同济医学院附属协和附属内分泌科,武汉 430022
    2. 湖北省糖尿病与代谢疾病临床研究中心,武汉 430022
余佳瑜,在读硕士研究生,专业方向:内分泌与代谢。E-mail: yujiayu19970821@163.com

收稿日期: 2022-05-31

  修回日期: 2022-08-10

  网络出版日期: 2022-09-07

Diagnosis, treatment and genetic analysis of a case of skin hyperpigmentation as the only manifestation with X-linked adrenoleukodystrophy

Expand
  • 1. Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
    2. Hubei Provincial Clinical Research Center for Diabetes and Metabolic Disorders, Wuhan 430022, China

Received date: 2022-05-31

  Revised date: 2022-08-10

  Online published: 2022-09-07

摘要

X-连锁肾上腺脑白质营养不良(X-linked adrenoleukodystrophy,X-ALD)是一种编码过氧化物酶体跨膜蛋白三磷酸腺苷结合盒亚家族D成员1(adenosine 5′-triphosphate binding cassette subfamily D member 1,ABCD1)基因突变的遗传病,其具有多种临床表现,从首发症状到致死性炎性脱髓鞘的进展过程极其快速。因此,识别早期临床症状,早诊断、早治疗能有效阻止该疾病进展。本研究报道1例少见的以“皮肤色素沉着3年”为唯一临床表型的X-ALD患者的实验室检查及影像学特点,并采用高通量测序为患者及其父母进行ABCD1基因测序。实验室检查结果提示患者肾上腺皮质功能减退,血清极长链脂肪酸浓度增高;肾上腺及脑MRI显示未见明显异常信号影。患者基因检测结果显示ABCD1基因外显子1发生c.521A>C半合子突变,其母亲为同位点杂合突变,故诊断为“X-连锁肾上腺脑白质营养不良”。随访过程中,患者肾上腺皮质功能不全症状没有改善,颅脑MRI显示右侧放射冠、左侧顶叶脑白质见少许点状高flair信号影,提示可能出现脑损伤。仅有皮肤表现而无神经系统异常的X-ALD患者极易被忽视,早期诊断并给予早期干预是延缓该疾病进展的重要途径。因此,建议所有的男性儿童患者以皮肤色素沉着为唯一临床表现,继而诊断肾上腺皮质功能减退时,都应该进行基因检测,及早鉴别X-ALD。

本文引用格式

余佳瑜, 陈婷, 王智华, 郑涓, 曾天舒 . 一例以皮肤色素沉着为唯一临床表现的X-连锁肾上腺脑白质营养不良的诊疗和基因检测分析[J]. 遗传, 2022 , 44(10) : 983 -989 . DOI: 10.16288/j.yczz.22-187

Abstract

X-linked adrenoleukodystrophy (X-ALD) is an inherited disease caused by a mutation in the adenosine 5′-triphosphate binding cassette subfamily D member 1 (ABCD1) gene encoding a peroxisomal transmembrane protein, which has various clinical manifestations and a rapid progression from initial symptoms to fatal inflammatory demyelination. Therefore, identification of early clinical symptoms and further early diagnosis as well as treatment can effectively prevent disease development. In this study, we reported the laboratory and radiographic features in a rare case of X-ALD with 3-year skin hyperpigmentation as the only manifestation. And the ABCD1 gene was sequenced for the patient and his parents by a high-throughput sequencing method. The results of laboratory examination showed adrenocortical hypofunction and increased serum concentrations of very long-chain fatty acids. Brain MRI showed no obvious abnormal signal shadow. A hemizygous mutation of c.521A>C was detected in the ABCD1 gene of the patient, and his mother has the same site heterozygous mutation. Therefore, this patient was diagnosed as “X-linked adrenoleukodystrophy”. During the follow-up, adrenocortical hypothyroidism did not improve, and brain MRI showed few high-FLAIR signals in the white matter of the right radial corona and left parietal lobe, suggesting possible brain injury. X-ALD patients with only skin manifestations but no neurological abnormalities are easily neglected, but early diagnosis and early intervention are important ways to delay the progression of this disease. Therefore, genetic testing for early X-ALD is recommended in all male children patients with skin pigmentation as the sole clinical presentation and subsequent diagnosis of adrenal hypofunction.

参考文献

[1] Moser AB, Fatemi A. Newborn screening and emerging therapies for X-linked adrenoleukodystrophy. JAMA Neurol, 2018, 75(10): 1175-1176.
[2] Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy-neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol, 2016, 12(10): 606-615.
[3] Ashrafi MR, Amanat M, Garshasbi M, Kameli R, Nilipour Y, Heidari M, Rezaei Z, Tavasoli AR. An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. Expert Rev Neurother, 2020, 20(1): 65-84.
[4] Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJA, Aubourg P, Poll-The BT. X-linked adrenoleukodystrophy (X-Ald): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis, 2012, 7: 51.
[5] Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr, 2005, 146(4): 528-532.
[6] Lee H, Ko JM, Lee SH. Generalized skin hyperpigmentation as the only manifestation of X-linked adrenoleucodystrophy. Br J Dermatol, 2020, 182(1): 239-240.
[7] Nan M, Liu YF, Zhao X, Yuan N, Chai SB, Zhang XM. A pedigree of X-linked adrenoleukodystrophy with hypocorticism. Chin J Intern Med, 2021, 60(2): 152-155.
[7] 南敏, 刘玉芳, 赵心, 袁宁, 柴三葆, 张晓梅. 一个以肾上腺皮质功能减退起病的X连锁肾上腺脑白质营养不良家系报道. 中华内科杂志, 2021, 60(2): 152-155.
[8] Barceló A, Girós M, Sarde CO, Pintos G, Mandel JL, Pàmpols T, Estivill X. De novo missense mutation Y174s in exon 1 of the adrenoleukodystrophy (Ald) gene. Hum Genet, 1995, 95(2): 235-237.
[9] Horikawa Y, Enya M, Yoshikura N, Kitagawa J, Takashima S, Shimozawa N, Takeda J. A first case of adrenomyeloneuropathy with mutation Y174S of the adrenoleukodystrophy gene. Neuro Endocrinol Lett, 2017, 38(1): 13-18.
[10] Ping LL, Bao XH, Wang AH, Pan H, Wu Y, Xiong H, Jiang YW, Qin J, Wu XR. Clinical features and genotype-phenotype studies of 89 Chinese patients with X-linked adrenoleukodystrophy. Chin J Intern Med, 2007, 45(3): 203-207.
[10] 平莉莉, 包新华, 王爱花, 潘虹, 吴晔, 熊晖, 姜玉武, 秦炯, 吴希如. X连锁肾上腺脑白质营养不良89例临床特征及基因型/表型关系. 中华儿科杂志, 2007, 45(3): 203-207.
[11] Rattay TW, Rautenberg M, Söhn AS, Hengel H, Traschütz A, Röben B, Hayer SN, Schüle R, Wiethoff S, Zeltner L, Haack TB, Cegan A, Schöls L, Schleicher E, Peter A. Defining diagnostic cutoffs in neurological patients for serum very long chain fatty acids (Vlcfa) in genetically confirmed X-adrenoleukodystrophy. Sci Rep, 2020, 10(1): 15093.
[12] Liberato AP, Mallack EJ, Aziz-Bose R, Hayden D, Lauer A, Caruso PA, Musolino PL, Eichler FS. MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. Neurology, 2019, 92(15): e1698-e1708.
[13] Mallack EJ, Turk BR, Yan H, Price C, Demetres M, Moser AB, Becker C, Hollandsworth K, Adang L, Vanderver A, Van Haren K, Ruzhnikov M, Kurtzberg J, Maegawa G, Orchard PJ, Lund TC, Raymond GV, Regelmann M, Orsini JJ, Seeger E, Kemp S, Eichler F, Fatemi A. Mri Surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: meta-analysis and consensus guidelines. J Inherit Metab Dis, 2021, 44(3): 728-739.
[14] Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol, 2007, 6(8): 687-692.
[15] Yu JY, Chen T, Guo X, Zafar MI, Li HQ, Wang ZH, Zheng J. The role of oxidative stress and inflammation in X-link adrenoleukodystrophy. Front Nutr, 2022, 9: 864358.
[16] Zhu J, Eichler F, Biffi A, Duncan CN, Williams DA, Majzoub JA. The changing face of adrenoleukodystrophy. Endocr Rev, 2020, 41(4): 577-593.
[17] Van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B, Wanders RJ, Barth PG. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's Oil". J Neurol Neurosurg Psychiatry, 1999, 67(3): 290-299.
[18] Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's Oil). Neurochem Res, 1994, 19(8): 1073-1082.
[19] Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, Armant M, Dansereau C, Lund TC, Miller WP, Raymond GV, Sankar R, Shah AJ, Sevin C, Gaspar HB, Gissen P, Amartino H, Bratkovic D, Smith NJC, Paker AM, Shamir E, O'Meara T, Davidson D, Aubourg P, Williams DA. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med, 2017, 377(17): 1630-1638.
文章导航

/